Christopher Hickey

Company: Arvinas, Inc.

Job title: Associate Director

Seminars:

PROTAC LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegenerative Diseases 8:30 am

Overview of Arvinas’ PROTAC strategy for neurodegenerative diseases Review of in vitro and in vivo data for potent, orally bioavailable PROTAC LRRK2 degrader molecules Biomarker changes in non-human primates consistent with LRRK2 PROTAC mechanism of actionRead more

day: Conference Day One

Panel Discussion – What Do We Need To Do To Get Protein Degraders To Clinic For Treating Neurodegenerative Disease? 10:00 am

How translatable are the current models to clinic and what do we need to advance them for approved use? What are the regulatory hurdles for protein degraders in neurodegenerative disease? What lessons have been learnt by past failures in neurodegenerative drug development that can inform the success of protein degraders? Read more

day: Conference Day One